A Phase I/II Study of Ganetespib in Combination With Doxorubicin

Inclusion Criteria: * Dose escalation phase: histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. OR safety dose expansion phase: histologically or cytologically confirmed relapsed or refractory small cell lung cancer * No more than 3 prior lines of chemotherapy; prior therapy with doxorubicin is permitted but no more than lifetime cumulative dose of 150 mg/m2; at least 3 weeks since prior chemotherapy or radiotherapy; at least 6 weeks if the last regimen included BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea bis-chloronitrosourea) or mitomycin C * Age \>/= 18 years * ECOG (Eastern Cooperative Oncology Group) performance status 0-1 * Life expectancy of greater than 3 months * Adequate organ and marrow function * Women of child-bearing potential must agree to avoid becoming pregnant and men must agree not to father a child for the duration of study participation. * Ability to understand and willingness to sign a written informed consent document Exclusion Criteria: * Chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier. * Receiving any other investigational agents * Untreated symptomatic brain metastases * History of allergic reactions attributed to compounds of similar chemical or biologic composition to ganetespib or other agents used in the study * Receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 or CYP2C18 * Left ventricular ejection fraction \< 50% * Known serious cardiac illness or medical conditions * uncontrolled inter-current illness including, but not limited to, ongoing or active infection, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant women * HIV-positive on combination antiretroviral therapy